drugset / Trial / NCT05620628
Ph2 Study of Savolitinib and Durvalumab (MEDI4736) Combination in Advanced MET Amplified Gastric Cancer(VIKTORY-2)
NaSingle-groupOpen-labelTreatment
Summary
For patients who failed primary chemotherapy with MET amplification, The efficacy and safety of the chemotherapy are evaluated by using dervalumab and saboritinib in combination.
Timeline
- Start
- 2023-01-05
- Primary completion
- 2026-12
- Completion
- 2027-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Durvalumab | Monoclonal antibody | 20 mg/kg | — |
| Subject | Durvalumab | Monoclonal antibody | 1500 mg | — |
| Subject | Savolitinib | Small molecule | 600 mg | Oral |